Cervarix news from FiercePharma
NewsIs Gardasil worth the cost?
Are HPV vaccines worth the cost? A study in the New England Journal of Medicine concludes that they aren't--at least not for women over 18. They'll only be cost-effective, the resesarchers decided,... Read more...
Glaxo's Cervarix delayed until late 2009
Call it a tale of two countries: Last week, the U.K. tapped GlaxoSmithKline's Cervarix as its preferred HPV vaccine, clearing the way for the National Health Service to put it on every young British... Read more...
U.K. inks HPV vaccine deal with Glaxo
Chalk up a vaccine win for GlaxoSmithKline. U.K. health officials have tapped GSK’s Cervarix as their official HPV preventative, passing over Gardasil, a longer-on-the-market shot marketed by... Read more...
France picks Gardasil over GSK upstart
Gardasil captured more territory for Merck and Sanofi-Aventis yesterday when French health officials recommended that vaccine against Human Papilloma Virus, or HPV. The French authority recommended... Read more...
It's Crestor vs. Lipitor in AZ trial
If GlaxoSmithKline can challenge Merck to a head-to-head trial (Cervarix versus Gardasil), then AstraZeneca... Read more...
Brits to vaccinate schoolgirls against HPV
The British government just made Merck's day--or was it GlaxoSmithKline's? U.K. schoolgirls will be vaccinated against the human papilloma virus that causes cervical cancer. And it's not just the 12-... Read more...
It's Merck v. Glaxo in vaccine battle
Call it the battle of the HPV vaccines. For the past week, either Merck's Gardasil or GlaxoSmithKline's Cervarix--or both--have captured headlines: • Glaxo submits Cervarix for approval in Japan... Read more...
| Press ReleasesPRESS RELEASE: GSK submits Cervarix licence application to Japan’s health authorities GSK submits Cervarix™ licence application to Japan’s health authorities For UK business and financial media (not for distribution to US media) Issued – 28 September 2007, London (UK) and Read more >> PRESS RELEASE: GSK seeks prequalification for Cervarix from the World Health Organization GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe For business and financial press only Issued — Thursday 4 October 2007, Read more >> |
Get more Cervarix coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
